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ABSTRACT
Objectives: We conducted a systematic review to
compare the efficacy and adverse events of autologous
haematopoietic stem cell transplantation (HSCT)
following high-dose chemotherapy (HDCT) versus
standard-dose chemotherapy (SDCT) in patients with
locally advanced or metastatic non-rhabdomyosarcoma
soft tissue sarcomas (NRSTS).
Setting: Patients were observed in hospital units
specialised for cancer therapy.
Participants: The review evaluated 294 patients with
19 different subtypes of malignant NRSTS. The
patients had a median age between 10 and 46 years
(range 2–65) and were mostly men.
Primary and secondary outcome measure: The
planned and measured primary outcomes were overall
survival and treatment-related mortality. The planned
and measured secondary outcomes were progression-
free survival, grade 3–4 non-haematological toxicity
and secondary neoplasia. Other secondary outcomes
including disease-free survival, event-free survival and
health-related quality of life were not reported.
Results: We included 62 studies reporting on 294
transplanted patients. We identified 1 randomised
controlled trial (RCT) with 38 transplanted and 45
non-transplanted patients and judged a low risk of bias.
We further identified 61 single-arm studies with 256
transplanted patients. Overall survival in the RCT was
reported not statistically significantly different between
autologous HSCT following HDCT versus SDCT. The HR
was 1.26 (95% CI 0.70 to 2.29; p=0.44) and the point
estimates at 3 years were 32.7% vs 49.4%. Data from
single-arm studies were used to extract data on adverse
events. Treatment-related mortality was reported in
5.1% (15 of 294) transplanted patients.
Conclusions: Overall survival in patients with locally
advanced or metastatic NRSTS was not statistically
different after autologous HSCT following HDCT
compared with SDCT in a single RCT with a total of 83
patients. No other comparative study was available. The
proportion of adverse events among the transplanted
patients is not clear.
INTRODUCTION
Soft tissue sarcomas (STS) are a highly
heterogeneous group of rare malignant solid
tumours of non-epithelial extraskeletal body
tissue and are classiﬁed on a histogenetic
basis.1 The location of the primary tumour
can involve any area of the body.2 STS can
involve any type of tissue and typically affect
muscles, tendons, adipose tissue, blood
vessels and joints and commonly present as a
painless mass.3 In this review, we investigated
Strengths and limitations of this study
▪ We conducted a comprehensive literature search
and strictly adhered to the projected methodology.
The WHO classification of soft tissue sarcomas
was adopted and modified to define a clear termin-
ology for the study selection process.
▪ We judged a low risk of bias for the single identi-
fied randomised controlled trial, which may serve
as the major relevant evidence.
▪ Single-arm studies provided some estimation
about serious adverse events with transplantation.
▪ Some treatments were performed 10–20 years
ago. Thus, the results may not be applicable to
patients who are treated today.
▪ The included studies report various subtypes of
non-rhabdomyosarcoma soft tissue sarcomas,
and each tumour type may carry an individual
risk profile and, therefore, ideally should be eval-
uated separately.
*This article is based on a Cochrane Systematic Review
published in the Cochrane Database of Systematic
Reviews (CDSR) 2013, Issue 8. Art. No.: CD008216. DOI:
10.1002/14651858.CD008216.pub4 (see http://www.
thecochranelibrary.com for information). Cochrane
Systematic Reviews are regularly updated as new
evidence emerges and in response to feedback, and the
CDSR should be consulted for the most recent version
of the review.
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non-rhabdomyosarcoma STS (NRSTS) provided that
they are categorised as malignant according to the
WHO 2002 classiﬁcation.4 In Western countries about
four new cases of NRSTS are estimated per 100 000
population every year, with the Ewing family of tumours
excluded from this statistic.5
Surgery is the standard treatment for localised NRSTS
and can be curative if distant dissemination is not
present.6 7 Chemotherapy is regarded mainly as a pallia-
tive treatment for high-risk patients who are charac-
terised by inoperable, locally advanced and metastatic
disease.6 Riedel8 provides an overview of current sys-
temic therapies and discusses possible novel therapeutic
agents and treatment strategies. High-dose chemother-
apy (HDCT) has been evaluated as an alternative treat-
ment option for high-risk patients. The rationale for
HDCT is that escalating doses of HDCT may increase
survival by capturing putatively remnant malignant
cells.9 The rationale for autologous haematopoietic stem
cell transplantation (HSCT) following HDCT is a
planned rescue for HDCT-related severe haematological
toxicity.9 The primary objective of the present systematic
review is to evaluate the effectiveness and adverse events
of autologous HSCT following HDCT in patients with
advanced or metastatic NRSTS.
METHODS
This article is based on a Cochrane systematic review
published in The Cochrane Library.10 Publication of this
work is in agreement with the policy of The Cochrane
Collaboration.11 While preparing this systematic review,
we endorsed the PRISMA statement, adhered to its prin-
ciples and conformed to its checklist.12
Study inclusion criteria
We included patients with NRSTS provided that they are
categorised as malignant according to the WHO 2013
classiﬁcation on STS4 as well as malignant haemangio-
pericytoma and anaplastic sarcoma. We excluded the
Ewing family of tumours according to the European
Society for Medical Oncology (ESMO) Guidelines
Working Group,5 chondrosarcomas, osteosarcomas and
rhabdomyosarcomas. While writing the Cochrane
Review, we referred to the WHO 2002 classiﬁcation.13
For the purpose of the present systematic review, we
updated the inclusion criteria and re-evaluated the
potentially relevant studies and included the following
entities: ‘Gastrointestinal Stromal Tumours’, ‘Malignant
peripheral nerve sheath tumour’, ‘Undifferentiated
pleomorphic sarcoma not otherwise speciﬁed’. Almost
all published studies refer to the 2002 classiﬁcation.
Thus, we continued to include the following entities
though they were removed and relocated within the
2013 classiﬁcation: ‘malignant ﬁbrous histiocytoma’
(MFH), ‘undifferentiated sarcoma’, ‘unclassiﬁed
sarcoma’, and ‘haemangiopericytoma’. Table 1 com-
pares the categories and malignant subtypes of the 2013
versus the 2002 edition of the WHO classiﬁcation of
tumours of soft tissue and indicates which of those are
included in the present systematic review. Participants
were included regardless of age, severity and clinical
stage of disease. Studies were included as long as at least
80% of patients had NRSTS and received the test inter-
vention. The test intervention was autologous HSCT fol-
lowing HDCT containing stem cells from peripheral
blood or bone marrow. The comparator was standard-
dose chemotherapy (SDCT). The primary outcomes
were overall survival and treatment-related mortality
(TRM). Secondary outcomes were disease-free survival,
progression-free survival, event-free survival, non-
haematological toxicity grades 3–4,14 secondary malig-
nant neoplasia and health-related quality of life.
Search strategy, selection of studies and data extraction
We conducted an electronic literature database search
in MEDLINE (Ovid), EMBASE (Ovid) and Cochrane
Library CENTRAL (Wiley) including articles published
from inception to an update search on 12 June 2014.
The corresponding search strategies have been pub-
lished in the corresponding Cochrane Review.10 We
retrieved all titles and abstracts by electronic searching
and downloaded them to the reference management
database EndNote V.X3.15 We considered studies written
in languages other than English. We searched the
online registries16 17 on 12 June 2014 for additional
completed or ongoing studies using the search strategy
"sarcoma AND chemotherapy AND transplantation". We
searched all retrieved abstracts of annual meetings con-
tained in EMBASE (Ovid). We contacted authors to
replenish missing information. All data assessments were
performed independently by two independent review
authors. We resolved differences by discussion or by
appeal to a third review author. We judged whether the
autologous HSCT following HDCT could be regarded as
a consolidation or a salvage therapy. A consolidation
therapy is a treatment that is given after cancer has dis-
appeared following the initial therapy and a salvage
therapy is a treatment that is given after the cancer has
not responded to other treatments.18 We considered a
consolidation therapy if the status at transplantation was
either a complete or a partial response to the preceding
therapy and we considered a salvage therapy if the status
was less favourable and in case a relapse was described.
Assessment of risk of bias in included studies
We have used four criteria from The Cochrane
Collaboration’s tool for assessing risk of bias in rando-
mised controlled trials (RCTs)19: random sequence gen-
eration, allocation concealment, blinding of outcome
assessment and selective reporting such as not reporting
prespeciﬁed outcomes. We extended the Cochrane tool
for assessing risk of bias by ﬁve criteria that consider
non-randomised studies: prospective design, comparable
baseline characteristics, assignment of patients to treat-
ment groups, concurrent control, and loss to follow-up.
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Table 1 Inclusion of malignant soft tissue tumours of the WHO classification 2013 vs 2012
Category Malignant subtypes 2013 2002 Inclusion
Adipocytic tumours 2013 2002 Included
Dedifferentiated liposarcoma 2013 2002 Included
Myxoid liposarcoma 2013 2002 Included
Pleomorphic liposarcoma 2013 2002 Included
Liposarcoma, not otherwise specified 2013 2002 Included
Round cell liposarcoma No 2002 Included
Mixed-type liposarcoma No 2002 Included
Fibrobastic/myofibroblastic tumours 2013 2002 Included
Adult fibrosarcoma 2013 2002 Included
Myxofibrosarcoma 2013 2002 Included
Low-grade fibromyxoid sarcoma 2013 2002 Included
Sclerosing epitheloid fibrosarcoma 2013 2002 Included
Malignant haemangiopericytoma No No Included
So-called fibrohistiocytic tumours 2013 2002 Included
Pleomorphic ‘MFH’/(UPS) No 2002 Included
Giant cell ‘MFH’/UPS with giant cells No 2002 Included
Inflammatory ‘MFH’/UPS with prominent inflammation No 2002 Included
Smooth muscle tumours 2013 2002 Included
Leiomyosarcoma (excluding skin) 2013 2002 Included
Pericytic (perivascular) tumours 2013 2002 No
Skeletal muscle tumours 2013 2002 No
Embryonal rhabdomyosarcoma 2013 2002 No
Alveolar rhabdomyosarcoma 2013 2002 No
Pleomorhic rhabdomyosarcoma 2013 2002 No
Spindle cell/sclerosing rhabdomyosarcoma 2013 No No
Vascular tumours of soft tissue 2013 2002 Included
Epithelioid haemangioendothelioma 2013 2002 Included
Angiosarcoma of soft tissue 2013 2002 Included
Chondro-osseous tumours 2013 2002 No
Mesenchymal chondrosarcoma 2013 2002 No
Extraskeletal osteosarcoma 2013 2002 No
Gastrointestinal stromal tumours 2013 No Included
Gastrointestinal stromal tumour, malignant 2013 No Included
Nerve sheath tumours 2013 No Included
Malignant peripheral nerve sheath tumour 2013 No Included
Epithelioid malignant peripheral nerve sheath tumour 2013 No Included
Malignant Triton tumour 2013 No Included
Malignant granular cell tumour 2013 No Included
Ectomesenchymoma 2013 No Included
Tumours of uncertain differentiation 2013 2002 Included
Synovial sarcoma NOS 2013 2002 Included
Epithelioid sarcoma 2013 2002 Included
Alveolar soft-part sarcoma 2013 2002 Included
Clear cell sarcoma of soft tissue 2013 2002 Included
Extraskeletal myxoid chondrosarcoma 2013 2002 No
Extraskeletal Ewing sarcoma 2013 2002 No
Desmoplastic small round cell tumour 2013 2002 Included
Extrarenal rhabdoid tumour 2013 2002 Included
Neoplasms with perivascular epithelioid cell differentiation 2013 2002 Included
Intimal sarcoma 2013 2002 Included
Malignant Mesenchymoma No 2002 Included
Undifferentiated/unclassified sarcomas 2013 No Included
Undifferentiated spindle cell sarcoma 2013 No Included
UPS 2013 No Included
Undifferentiated round cell sarcoma 2013 No Included
Undifferentiated epithelioid sarcoma 2013 No Included
Undifferentiated sarcoma NOS 2013 No Included
MFH, malignant fibrous histiocytoma; NOS, not otherwise specified; UPS, undifferentiated pleomorphic sarcoma.
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We applied The Cochrane Collaboration’s criteria for
judging risk of bias.20
Data synthesis
We synthesised aggregate data as narrative because data
were too scarce to be pooled. Differently from the
Cochrane Review, we did not pool time-to-event data on
overall survival from studies with individual data. With
respect to survival data, we accepted time of diagnosis
and beginning of treatment as starting points. We evalu-
ated all 62 studies to search for reports on TRM and
tabulated the identiﬁed patient data. We evaluated the
seven studies reporting aggregate data to search for
reports on grade 3–4 non-haematological toxicity in the
autologous HSCT following the HDCT arm and tabu-
lated the identiﬁed event data.
RESULTS
Search results
Figure 1 shows the literature search and study ﬂow. We
retrieved 1035 records and evaluated 260 full text
papers in detail. We included 62 studies with 294 trans-
planted patients, 1 RCT with 38 transplanted and 45
non-transplanted patients,21 6 single-arm studies report-
ing aggregate case series data,22–27 and 55 single-arm
studies with individual data. In online registries, we
Figure 1 Literature search and study flow.
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identiﬁed 6 studies with a still pending completion and
we did not ﬁnd additional studies in the update search.
Baseline data
We provide an overview of the main characteristics of
studies and treatment (table 2), of the patients (table 3)
and of the frequency of the identiﬁed subtypes
(table 4). The one RCT was an open, multicenter and
randomised phase III study with two parallel treatment
groups.21 Patients were eligible for randomisation if they
had responded to chemotherapy or, for stable disease, if
a complete surgical resection of all disease sites could be
carried out. The intention-to-treat principle was modi-
ﬁed to exclude patients found to be ineligible at a histo-
logical review after randomisation. Three of the six
single-arm studies reporting aggregate case series data
collected the data prospectively22–24 and three
retrospectively.25–27 Data from the remaining 55 single-
arm studies were considered for the description of TRM
only.
The 62 studies were set in 13 different countries in
four different continents. Most of the transplanted
patients were studied in France, USA and Germany. We
assume that most patients in the studies reporting aggre-
gate case series data received autologous HSCT follow-
ing HDCT as a consolidation therapy, whereas a
considerable number of the individual case data were
associated with autologous HSCT following HDCT as a
rescue therapy. The majority of all studies used periph-
eral blood stem cell transplants. Median age varied
roughly between 19 and 46 years and there was a male
preponderance. Patients had 19 different relevant histo-
logical diagnoses. Most patients had desmoplastic small
round-cell tumour (N=109 of 294) followed by the new
Table 2 Characteristics of studies and therapy
Study
Number of
centers
(country)
Enrolment;
years
Prospective
design
Autologous HSCT following HDCT
Drugs
Consolidation
vs salvage vs
NR; N
PBSCT vs BMT
vs NR; N
Aggregate comparative data
Bui-Nguyen et al21 16 (France) 2000–2008 Yes Ca-Et-If 38 vs 0 vs 0 38 vs 0 vs 0
Aggregate case series data
Bertuzzi et al22 1 (Italy) 1997–2002 Yes Me-Mi-Th 10 vs 0 vs 0 10 vs 0 vs 0
Bisogno et al23 >1 (Italy) 1999–2008 Yes Cy-Me-Th 14 vs 0 vs 0 14 vs 0 vs 0
Blay et al24 1 (France) 1988–1994 Yes Ci-Et-If 0 vs 0 vs 24 0 vs 0 vs 24
Bokemeyer et al25 3 (Germany) NR No Do-If 16 vs 0 vs 0 16 vs 0 vs 0
Cook et al26 29 (USA) 1999–2007 No Ca-Cy-Et-Me-Th 0 vs 0 vs 36 33 vs 2 vs 1
Philippe-Chomette
et al27
>1 (France) 1995–2006 No Various 14 vs 0 vs 0 0 vs 0 vs 14
Individual cases data
55 studies (142
patients)
Various Various No Various 69 vs 61 vs 12 102 vs 21 vs 19
BMT, bone marrow transplant; Ca, carboplatin; Ci, cisplatin; Cy, cyclophosphamide; Do, Doxorubicin; Et, etoposide=Vepesid=VP 16;
HDCT, high-dose chemotherapy; HSCT, autologous haematopoietic stem cell transplantation; If, ifosfamide; Me, melphalan; Mi, mitoxantrone;
N, number; NR, information not reported in the article; PBSCT, peripheral blood stem cell transplant; Th, thiotepa.
Table 3 Characteristics of patients
Study
Patients
analysed; N
FU Subtypes
Age; median years (range)
Gender; %
males
HSCT SDCT HSCT SDCT HSCT SDCT
Aggregate comparative data
Bui-Nguyen et al21 38 45 55 (NR) Various 46 (19 to 65) 43 (18 to 65) 58 50
Aggregate case series data
Bertuzzi et al22 10 NA 35 (14 to 60) DSRCT 29 (NR) NA 100 NA
Bisogno et al23 14 NA 27 (NR) DSRCT 10 (2 to 17) NA 93 NA
Blay et al24 24 NA NR Various NR NA NR NA
Bokemeyer et al25 16 NA NR Various 45 (25 to 57) NA NR NA
Cook et al26 36 NA 44 (4 to 89) DSRCT 19 (8 to 46) NA 80 NA
Philippe-Chomette et al27 14 NA 23 (9 to 51) DSRCT NR (4 to 29) NA 86 NA
Individual cases data
55 studies 142 NA Various Various 25 (1 to 65) NA NR NA
DSRCT, desmoplastic small-round cell tumour; FU, follow-up of the analysed patients in median months (range); HSCT, autologous
haematopoietic stem cell transplantation following high-dose chemotherapy; N, number; NA, not applicable; NR, information not reported in
the article; SDCT, standard-dose chemotherapy.
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category of undifferentiated pleomorphic sarcomas
(N=61), which is composed of MFH (N=31), unclassiﬁed
sarcoma (N=17) and undetermined sarcoma (N=13).
Primary outcome
Overall survival was not statistically signiﬁcantly different
in the RCT by Bui-Nguyen et al21 between autologous
HSCT following HDCT versus SDCT regarding the HR of
1.26 (95% CI 0.70 to 2.29; p=0.44; table 5). In this RCT,
the point estimates at 3 years were 32.7% vs 49.4% based
on 8 vs 17 remaining patients at risk. The patients at risk
at baseline were 38 vs 45 patients. With respect to the
studies reporting aggregate case series data, overall sur-
vival for transplanted patients ranged roughly from 20%
to 51% at 2 years and from 32% to 40% at 3 years
(table 5). In 10 studies, TRM was associated with 15 of
137 evaluated patients (table 6). Assuming no other TRM
in the remaining 157 patients, a risk o procedure-related
death might be estimated as 5.1% (15 of 294).
Secondary outcomes
Progression-free survival was also not statistically signiﬁ-
cantly different in the RCT by Bui-Nguyen et al21
between autologous HSCT following HDCT versus
SDCT regarding the HR of 1.34 (95% CI 0.81 to 2.20;
p=0.25). In this RCT, the point estimates at 3 years were
9.3% vs 21.6% based on 3 vs 12 remaining patients at
risk. The RCT did not report results on disease-free sur-
vival and event-free survival. An overview of the number
of events of non-haematological toxicity grade 3–4 is
provided in table 7. In the RCT, 11 events were observed
in 38 transplanted patients and 1 event (asthenia) was
reported regarding the SDCT arm. In 3 of the studies
reporting aggregate case series data, 25 events were
observed in 54 transplanted patients in the HSCT arm.
The other 3 studies did not report toxicity data. We
identiﬁed one secondary neoplasia in a single case
report. Health-related quality of life scales were not
addressed in the included studies.
Data quality
Clinical heterogeneity was substantial because tumour
subdiagnosis varied considerably between patients.
Furthermore, tumour stage and metastasis were not
reported for all participants. The RCT by Bui-Nguyen
et al21 stands out as it is the only study reporting com-
parative data. We judged a low risk of bias for this trial
for random sequence generation and selective
Table 4 Frequency of subtypes
Subtype All Aggregate Individual
Anaplastic sarcoma 5 0 5
Angiosarcoma 10 4 6
Clear cell sarcoma 2 1 1
Desmoplastic small round
cell tumour
109 74 35
Epitheloid sarcoma 2 0 2
Fibrosarcoma 6 1 5
Fibromyosarcoma 1 0 1
Leiomyosarcoma 29 14 15
Liposarcoma 15 8 7
Mesenchymal sarcoma 2 2 0
Malignant fibrous
histiocytoma
31 13 18
Malignant
haemamgiopericytoma
8 5 3
Malignant peripheral nerve
sheath tumour
4 0 4
Rhabdoid tumour,
extrarenal, extracerebral
2 0 2
Spindle cell sarcoma 1 0 1
Synovial sarcoma 32 9 23
Unclassified sarcoma 17 12 5
Undetermined sarcoma 13 4 9
Not NRSTS 5 5 0
Total number 294 152 142
NRSTS, non-rhabdomyosarcoma soft tissue sarcomas.
Table 5 Overall survival in studies reporting aggregate data
Study
Overall survival (95% CI), point estimates
StatisticsHSCT at 2 years HSCT at 3 years
SDCT at
3 years
Aggregate comparative data
Bui-Nguyen et al21 32.7% 49.4% HR 1.26 (0.70 to 2.29),
p=0.44
Aggregate case series data
Bertuzzi et al22 20% NR NA
Bisogno et al23 48% 38.9% NA
Blay et al24 NR NR NÁ
Bokemeyer et al25 Median 13 months,
range 3–19
NA
Cook et al26 NR 40% (24% to 58%) NA
Philippe-Chomette et al27 51.4% (23.2% to 79.6%) NR NA
Some estimates were deduced from Kaplan-Meier plots.
HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; NA, not applicable; NR, not reported, SDCT,
standard-dose chemotherapy.
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reporting. However, the trial does have some drawbacks.
We judged an unclear risk for allocation concealment
because masking of allocation was not described in full
detail. We judged a high risk of bias for blinding of
outcome assessment because it was not reported for any
outcome. The other 61 of 62 studies are single-arm
studies and are therefore not qualiﬁed for assessing a
treatment effect.
DISCUSSION
Outcomes
We identiﬁed one RCT comparing autologous HSCT fol-
lowing HDCT versus SDCT.21 The authors reported a
difference in overall survival and progression-free sur-
vival after the treatment in favour of SDCT but the dif-
ference was not statistically signiﬁcant, respectively.
Therefore, there is evidence that patients may not have
a better survival after autologous HSCT following HDCT
versus SDCT. If at all, this intervention should only be
offered after careful consideration and preferably only
within a randomised controlled clinical trial. We esti-
mated a TRM of 5.1%, which was somewhat higher than
the 2% reported by others.28 Severe toxicity grade 3–4
was sparsely reported. Studies on health-related quality
of life were not identiﬁed. The frequency of secondary
neoplasia in 1 of 294 participants is probably an extreme
underestimation of the true frequency due to a relatively
short follow-up. The detection of secondary neoplasia
depends on a long follow-up and was estimated from 4%
to 6.9% by others.29 30
The WHO 2013 classification
The WHO recently published the 2013 classiﬁcation on
STS.4 The authors inserted the category ‘Undifferentiated
Pleomorphic Sarcoma Not Otherwise Speciﬁed’ to lodge
those types of STS that are difﬁcult to classify using the
current available techniques.31 32 The authors integrated
the terms ‘MFH’, ‘Undifferentiated Sarcoma’, and
‘Unclassiﬁed Sarcoma’ into this newly created category.
MFH was characterised by an apparent lack of speciﬁc
differentiation33 and it was considered a diagnosis of exclu-
sion.34 MFH was regarded as the most common soft tissue
sarcoma of adulthood33 and accounted for up to 25% of
patients in clinical trials on soft tissue sarcoma.34 In 1992,
Fletcher33 reassessed 159 cases with MFH and found 63%
Table 6 Treatment-related mortality in the HSCT arm of all included studies
Study
N affected/
N evaluated patients Specification
Treatment-related mortality
Bui-Nguyen et al21 1/38 Treatment-related leukaemia death 2 years after HSCT
Cook et al26 2/36 NR
Doros et al41 1/1 NR
Engelhardt et al42 3/24 Sepsis (N=2); pneumonia related to lung metastases (N=1)
Kasper et al43 1/14 Cardiac arrest of unknown cause
Matsuzaki et al44 1/1 Multiple organ failure
Navid et al45 1/2 Liver as well as kidney failure
Philippe-Chomette et al27 1/14 Died of treatment toxicity 12 months after HSCT
Saab et al46 2/4 Acute myocardial infarction (N=1); veno-occlusive disease (N=1)
Slease et al47 2/3 Progressive encephalopathy (N=1); sepsis (N=1)
Total 15/137
HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; N, number; NR, not reported.
Table 7 Grade 3–4 NCI-CTCAE non-haematological
toxicity in the HSCT arm of studies reporting aggregate
case series data
Study
N events/
N evaluated
patients Specification
Aggregate comparative data
Bui-Nguyen et al21 11/38 Digestive (N=8);
infection (N=2);
pain (N=1)
Aggregate case series data
Bertuzzi et al22 NR NA
Bisogno et al23 1/14 Mucositis grade 4
Blay et al24 16/24 Neurological grade
4 (N=1); lung grade
3/4 (N=2); renal
grade 3/4 (N=5);
nausea/vomiting
grade 3/4 (N=8)
Bokemeyer et al25 8/16 No grade 4;
neurological (N=1);
renal (N=2);
infection (N=1);
mucositis (N=2);
nausea/emesis
(N=2)
Cook et al26 NR NA
Philippe-Chomette
et al27
NR NA
HSCT, autologous haematopoietic stem cell transplantation
following high-dose chemotherapy; N, number; NA, not applicable;
NR, not reported; NCI-CTCAE, National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE) grade
III–IV.14
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(97 of 159) tumours to be speciﬁc sarcomas other than
MFH. In 2001, Fletcher et al35 conﬁrmed that 84% (84 of
100) tumours of patients with MFH showed sufﬁcient dif-
ferentiation to assign them to speciﬁc subtypes of STS.
The techniques to assess cell differentiation have been sub-
stantially improved with the effect that the frequency of
the tumour within this category has decreased.36 It was
supposed that the category of ‘Undifferentiated Sarcoma
—Otherwise Not Speciﬁed’ may contain liposarcoma,
ﬁbrosarcoma, leiomyosarcoma, rhabdomyosarcoma, other
sarcomas, and even carcinomas or lymphomas.36 37 It was
estimated that the pathologist might have difﬁculties in
identifying a speciﬁc differentiation in 10–15% of tumours
previously called MFH.37 The new edition also removed
the term ‘Haemangiopericytoma’.31 32 ‘Gastrointestinal
Stromal tumours’ and ‘Nerve Sheath tumours’ were relo-
cated from other classiﬁcations and appear for the ﬁrst
time in the soft tissue classiﬁcations.31 32 Consequently, the
term ‘Malignant Peripheral Nerve Sheath Tumour’ is
newly integrated.
Strengths and limitations
The search strategy had the broad aim of the retrieval of
all relevant studies. With respect to historical versions of
the Cochrane Review,10 we applied two different search
strategies and retrieved the same studies with aggregate
data but different studies with individual cases data.
These results show the substantial difﬁculty associated
with the aim of searching for all published cases. This
enterprise appears almost impossible. We adopted the
new WHO 2013 classiﬁcation of STS and made minor
modiﬁcations to deﬁne a clear terminology for the study
selection process. The group of NRSTS consists of many
subtypes that are difﬁcult to diagnose and separate even
today. A considerable number of tumours cannot be
clearly assigned to a speciﬁc histological category. Thus,
we may have tumours with a speciﬁc label that might
not be true. Otherwise, we may have tumours without a
speciﬁc label that might belong to a speciﬁc category.
We excluded studies if the proportion of non-eligible
participants were greater or equal to 20% of the total
population to prevent a signiﬁcant mixture with disease
or interventions that are not included in the present
review. Authors were contacted to ask for additional
data. We judged a low risk of bias for the one identiﬁed
RCT, which may serve as the major relevant evidence.
All other identiﬁed studies were single-arm studies that
are not helpful in deciding whether autologous HSCT
following HDCT for NRSTS is a meaningful treatment
option. Therefore, we removed the survival data of
studies reporting individual data. Nevertheless, they pro-
vided data for estimation about TRM within all included
transplanted patients. We also removed data on non-
haematological toxicity of studies reporting individual
data because the sparse reporting might have caused a
display of non-representative information. The descrip-
tion of consolidation and salvage therapy is based on
our judgement and might be judged differently by
others. These types of therapy were not precisely
reported in most studies. Some treatments were per-
formed 10–20 years ago. Thus, the results may not be
applicable to patients who are treated today. All studies
report various subtypes of NRSTS and each tumour type
may carry an individual risk proﬁle and, therefore,
ideally should be evaluated separately. With respect to
the individual survival data, follow-up started at different
time points, that is, at diagnosis or at start of treatment.
The delay between diagnosis and starting HDCT can be
considerable.
Other findings and opinions
We wish to point out that some authors have warned
against the use of autologous HSCT following HDCT,
indicating the possibility of repositioning of malignant
cells.38 Others have questioned the use of HDCT with
reference to the potential existence of refractory cancer
stem cells.9 Pedrazzoli et al39 stated that the potential
beneﬁt of this treatment option has not been investi-
gated sufﬁciently in comparative studies. Kasper et al40
concluded that the use of HDCT for locally advanced or
metastatic adult (soft tissue and bone) sarcomas still
remains highly investigational and should not be per-
formed outside clinical trials. The identiﬁed RCT by
Bui-Nguyen et al21 provides meaningful comparative data
for the ﬁrst time and its results questions any beneﬁt of
the intervention. Finally, we cannot close the chapter as
it can be unsecure to rely on a single trial.
CONCLUSION
Overall survival in patients with locally advanced or
metastatic NRSTS was not statistically different after
autologous HSCT following HDCT compared with
SDCT in a single RCT with a total of 83 patients. No
other comparative study was available. A considerable
number of patients were not evaluated concerning
adverse events, and its proportion among the trans-
planted patients remains unclear. If this treatment is
offered it should only be after careful consideration and
only within an RCT.
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